pl endorphin were measured in patients with acute and chronic heart failure and cardiogenic shock. A subgroup of eight patients with New York Heart Association (NYHA) class III-IV heart failure was assessed for acute haemodynanmic effects of naloxone, an opioid receptor antagonist. A separate group of 10 patients with class II-III heart failure, was randomised to a double blind placebo controlled study of the effects of intravenous naloxone on cardiopulmonary exercise performance.
Results-Plasma concentrations of fp endorphin were usually normal in patients with chronic heart failure and did not correlate with severity as assessed by NYHA class. In 29% of patients with acute heart failure and 71% of those with cardiogenic shock p endorphin concentrations were high. The median concentration in the cardiogenic shock group was significantly higher than in either of the two heart failure groups and there was some evidence of a relation between pf endorphin concentrations and survival.
At the doses tested, naloxone was unable to modify systemic haemodynamics, exercise performance, or symptoms in patients with chronic congestive heart failure.
Conclusions-Circulating concentrations of fp endorphin are usually normal in patients with chronic congestive heart failure. Inhibition of the endogenous opioid system is unlikely to have therapeutic potential in heart failure. 
Symptoms
Visual analogue scales for dyspnoea and fatigue were displayed on the monitor of a BBC microcomputer as horizontal uncalibrated bars, annotated with the words "none" at one end and "severe" at the other. With a linear potentiometer mounted on the treadmill and inputting directly to the microcomputer, patients were able to indicate their estimation of the severity of the relevant symptom during exercise by moving the position of a cursor from extreme left (equivalent to a score of 0) to extreme right (a score of 100). The modified Borg scale was also used at peak exercise. As a measure of dyspnoea, both visual analogue scales and the Borg score correlate well with measured ventilation, the relation being predominantly linear.
Protocol
At least two practice tests and all of the exercise tests were performed between 0900 and 1200. Immediately before each of the three study exercise tests and after the patients were breathing through the closed respiratory loop of the gas analysing system, each patient received in a double blind randomised order, either placebo or naloxone (0x1 mg.kg-I or 1*0 mg.kg-1) given as a slow bolus intravenous injection over one minute. End points in this study were breathlessness and fatigue assessed as already described and the following measures of cardiovascular and respiratory performance: exercise time, maximal 02 consumption (Vo,max) and CO2 production (Vco,), transcutaneous 02 and CO2 saturation, 02 consumption at the anaerobic threshold, ventilation (VE), respiratory dead space, and tidal volume. Symptoms were assessed twice during exercise; firstly when the patient had reached 60% of his previously found VO2max and secondly at peak exercise. Peripheral venous blood samples were drawn from an indwelling cannula before and after exercise and assayed for naloxone, fi endorphin, ACTH, and cortisol.
DATA ANALYSIS
In the observational study, ,B endorphin, ACTH, and cortisol results were skewed and so are reported as median (interquartile range) with groups being compared by MannWhitney U tests. Rank correlation coefficients were calculated by Spearman's method. Open label naloxone was given in the haemodynamic studies but the data were digitised and analysed on line by microcomputer. This removed, to some extent, the problems of within-observer variability and bias. Accordingly, further analysis by an independent observer was not performed. Haemodynamic and exercise variables were normally distributed and are reported as mean(SD) or mean(SEM). Group comparisons were made by repeated measures or one way analysis of variance followed by modified t tests if appropriate.
Results fi ENDORPHIN CONCENTRATIONS IN PATIENTS WITH HEART FAILURE OR CARDIOGENIC SHOCK
The number of patients with concentrations >the upper limit of normal was three of 34 (9%) with chronic heart failure, eight of 28 (29%) with acute heart failure, and 10 of 14 (71%) with cardiogenic shock (fig 1 and table  1) . Median values in the heart failure groups were not significantly different from each other. Two of the three patients with chronic heart failure and high concentrations were in NYHA class III (ft endorphin 8-2 and 10-2 pmol.1-') and the other was in class IV (ft endorphin 13-3 pmol.1-'). Patients with cardiogenic shock had significantly higher concentrations than either of the two heart failure groups. The four patients with cardiogenic -50  M  III  IHD  15  160  -56  M  IV  IHD  15  80   -48  M  III  IHD  17  80   -49  M  IV  IHD  20  250   -60  M  III  IHD  21  120   -56  M  III  IHD  25  240   -24  M  Ill-IV  DCM  19 80 -Exercise study (n = 10) 61 M  III  IHD  22  120  48  56  M  II  IHD  29  120  73  53  M  II  IHD  25  40  91  30  M  II  IHD  10  160  72  54  M  II  IHD  28  40  71  38  M  II  IHD  18  40  79  59  M  II  IHD  20  80  68 pmol.1-' v 13'6 (6 4-250) pmol.l-1 P = 0o001).
Relation between fi endorphin concentrations and other neuroendocrine and clinical variables Table 1 shows that median ACTH concentrations were similar in the two heart failure groups but patients with cardiogenic shock had a significantly higher ACTH concentration than those with chronic heart failure. There was a significant positive correlation between fi endorphin concentrations and ACTH (r = 0-58, P = 0-00001, n = 76).
Median cortisol concentrations in each of the three groups were significantly different from each other. There was a weak positive correlation between cortisol and fi endorphin concentrations (r = 0-36, P = 0003, n = 70). Within all patients, univariate rank correlation analysis showed no significant relation between fi endorphin concentrations and any of the following: age, aetiology of heart failure, heart rate, systolic and diastolic blood pressure, jugular venous pressure, simultaneously measured concentrations of creatinine or angiotensin II, left ventricular ejection fraction, and the daily dose of frusemide. There was a weak but significant correlation between fi endorphin and arginine vasopressin (r = 0A46, P = 0 005, n = 38). fi endorphin concentrations were not different in patients with and without cardiomegaly or pulmonary oedema.
Considering only the patients with chronic heart failure, there were no significant correlations between fi endorphin concentration and either New York Heart Association (NYHA) class or the use of angiotensin converting enzyme (ACE) inhibitors. In six patients fi endorphin was measured before and one week after the start of treatment with captopril. The plasma concentration increased in five of six patients and was unchanged in the sixth; median (interquartile range) concentration before treatment was 4 0 (36-5-0) pmol.1-' v 4-4 (3-7-5-8) pmol.1-' one week later, P = 0*10. Table 2 shows the clinical characteristics of the eight patients included in this study. Their mean age was 52 (range 24-70) and all were in NYHA class III-IV. In six of eight patients the aetiology of their heart failure was ischaemic heart disease, the other two patients had dilated cardiomyopathy. The mean left ventricular ejection fraction was 19% (range 15-25%) and the mean daily dose of frusemide was 145 (range 80-250) mg.day-1. No adverse effects were reported during the naloxone infusion by any of the patients. Naloxone had no significant effects on any of the variables measured (table 3). 
ACUTE HAEMODYNAMIC EFFECTS OF NALOXONE IN PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE

EFFECTS OF NALOXONE ON EXERCISE CAPACITY AND SYMPTOMS IN HEART FAILURE
A total of 22 screening exercise tests were performed to identify 10 suitable subjects (table  2) . The 10 patients were all men, aged from 30-65, and all were in NYHA functional class II-III with left ventricular ejection fractions ranging from 10-29%. In one case, the aetiology of the heart failure was idiopathic dilated cardiomyopathy and in the others it was ischaemic heart disease. The mean daily dose of frusemide was 92 mg and all of the patients except one were receiving treatment with ACE inhibitors.
Cardiopulmonary exercise variables
All 10 patients successfully completed each of their three study exercise tests. Neuroendocrine variables Before exercise, concentrations of fi endorphin were similar at each of the three exercise tests (F=,0-02, P > 0 80). Within each group, concentrations after exercise were significantly higher after naloxone but not after placebo. Naloxone enhanced the exercise induced increase in fi endorphin concentrations in a dose dependent manner (F = 4 35, P = 0 03). Measurements of ACTH and cortisol were only available for eight patients. In 20 of 48 samples assayed, ACTH concentrations were below the lower limit of detection of the assay (2 pmol.1 -). In these patients an arbitrary value of 1 pmol.1-I was inserted and the subsequent statistical comparisons were made with non-parametric techniques. The ACTH and cortisol concentrations were increased by exercise but none of the within group differences reached significance.
Plasma naloxone concentrations
After the lower dose of naloxone, mean plasma concentrations ranged from 0-05-1-56 ,umol.l-1 after exercise. The 10-fold higher dose increased plasma concentrations by an average of 26-fold with all patients exceeding 1 umol.l-' and two exceeding 10/umol.l-': range 1-04-22-10pumol.1-1. There were weak correlations between the plasma concentration of naloxone at the end of exercise and both the endorphin concentration after exercise(r = 048, P = 0 04) and the percentage change in fi endorphin concentrations induced by exercise (r = 0A43, P = 0 07).
Correlations between f/ endorphin concentrations and exercise performance Simple linear regression analysis showed no significant correlations between,B endorphin concentrations before or after e-xercise and any variable of cardiopulmonary exercise performance. This finding was consistent whether each of the three treatment groups were examined separately or together. There was also no correlation with visual analogue scores for fatigue, but in the placebo group, scores for dyspnoea correlation with concentrations after exercise (r = -0 70, P = 0 04). This relation was lost when the patients exercised after being given either a low dose (r = 0A44, P = 0 23) or high dose (r = 0A43, P = 0-25) of naloxone.
Discussion fi ENDORPHIN CONCENTRATIONS IN PATIENTS WITH HEART FAILURE
Kawashima et al reported a good correlation between NYHA class and endorphin concentration in 37 patients with chronic congestive heart failure.22 In a similar group of patients with heart failure we found high ,B endorphin concentrations in only three patients and could not show any relationship with NYHA class. A larger proportion of our patients with acute heart failure and most of those with cardiogenic shock had high ,B endorphin concentrations. The significant differences between ,B endorphin concentrations in those patients surviving their stay in hospital both in the whole group and particularly in those with cardiogenic shock are intriguing. There may be some relation between the magnitude of a haemodynamic disturbance and the stimulus to opioid peptide release.
OPIOID PEPTIDES AND ACE INHIBITORS
The exercise induced euphoria reported by endurance athletes has been attributed to enhanced release of endogenous opioid peptides.2324 This has also been offered as an explanation for the uplifting effect on mood of ACE inhibitors.2526 In normal subjects, captopril did not increase concentrations of leu-enkephalin and met-enkephalin either before or after exercise, but it did enhance the exercise induced rise in the plasma concentration of endorphin. In our patients with chronic heart failure, ,B endorphin concentrations were not higher in those taking an AGE inhibitor. In the six patients in whom concentrations were measured before and one week after the start of ACE inhibitor treatment, there was a trend towards higher concentrations. The failure of our study and a similar previous study27 to reproduce these haemodynamic effects in patients with severe congestive heart failure may be due to several differences between clinical heart failure in humans and that in the particular animal model used by Liang et al. 4 whether there is an exercise threshold required to provoke a rise in plasma endorphin in heart failure-as there is in normal people, nor whether the degree of enhancement by naloxone reflects the underlying concentration of activation within the endogenous opioid system. In our patients, there was no relation between exercise intensity and fi endorphin concentrations before or after exercise, but in 16 patients with dilated cardiomyopathy, Kawashima's group found that JJ endorphin concentrations before exercise were inversely correlated with exercise capacity.22
Modulation of opioid receptors may alter the perception of breathlessness in patients with heart failure. Davies et al found that naloxone, given intravenously immediately before exercise, increased the sensation of dyspnoea at a standard workload and slightly reduced Vo2max. By contrast, dihydrocodeine, an opioid receptor agonist, reduced dyspnoea and increased Vo2max. In a finding analogous to that described previously in patients with angina, objective measures of pain sensation correlated with indices of dyspnoea. 34 The opposite results obtained with the antagonist and agonist in these patients suggested that these effects were receptor mediated. Opioids modify the respiratory response to hypercapnia, but no data on CO2 production or ventilation were provided. In a second study morphine was given through a nebuliser to patients with heart failure. In this case, the opioid agonist did not reduce either the sensation of dyspnoea or maximal ventilation. Despite this, slight but significant improvements in exercise duration and Vo2max were again found.35 In our patients with heart failure, intravenous naloxone had no effect on either symptom perception or exercise capacity. Our patients were similar in age and severity of heart failure to those studied by Kawashima et al 22 Teleologically, it has been postulated that endorphins are critical to the coping mechanisms .and survival of the organism. In a quiescent state when blood pressure is normal, opioids are not released and giving an opioid antagonist has, as in our patients, no detectable effect. After a stress such as major haemorrhage, endorphins are released and contribute to analgesia and hypotension. Hypotension may be a highly protective mechanism by reducing the driving pressure in the bleeding vessels and assisting coagulation. Under certain conditions, however, particularly septic shock, endogenous opioid peptide release may be less helpful and opioid receptor antagonists can produce dramatic improvements in blood pressure.3637 In response to other, evolutionary younger stresses, such as acute myocardial infarction, release of opioid peptide may be similarly inappropriate.
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